Out in Front – Effective Pre-approval Communication with Payers

June 2, 2020




Optimizing medicine Improving lives.

Disclaimer

Organizations may not re-use material presented at this AMCP webinar for commercial purposes without the written consent of the presenter, the person or organization holding copyright to the material (if applicable), and AMCP. Commercial purposes include but are not limited to symposia, educational programs, and other forms of presentation, whether developed or offered by for-profit or not-for-profit entities, and that involve funding from for-profit firms or a registration fee that is other than nominal. In addition, organizations may not widely redistribute or re-use this webinar material without the written consent of the presenter, the person or organization holding copyright to the material (if applicable), and AMCP. This includes large quantity redistribution of the material or storage of the material on electronic systems for other than personal use.



How to Ask a Question





Panelists

Moderator









Lisa Cashman, PharmD, Vice President, Specialty Solutions, MedImpact Healthcare Systems Laura Randa, Vice President Market Access, HEOR and Public Policy, Mycovia Pharmaceuticals Jay Jackson, PharmD, MPH, Senior Vice President, Consulting, Xcenda Laurie Fazio, Head, FormularyDecisions Market Access Solutions & Growth Strategies



Webinar Overview

In this session, you will learn:

- The latest research, industry trends and guidelines around pre-approval information exchange (PIE)
- Payer perspectives on PIE that are impactful in their decision making
- Manufacturer best practices and processes for PIE to meet the needs of payers
- Virtual opportunities for key stakeholders to connect and share critical product information



Polling Question


What is your level of experience with PIE?

I have only used PIE to find the circumference of a circle	33%
Starting to consider use of PIE within my organization	21%
Have engaged in PIE, but have challenges with implementation	33%
Consistently engage in PIE with few limitations	13%



Legislative Evolution of PIE and HCEI Communication





Key: FDAMA – Food and Drug Administration Modernization Act; HCEI – healthcare economic information; H.R. – House Resolution; PIE – pre-approval information exchange.



CONFIDENTIAL

Role of PIE in product development



payers:
forecasting for
re value-based
approval pathway hity to discuss and
pies
ap





PROCESS



Two-thirds of manufacturers have a process/guidance for approval of PIE materials



Note: Percentages may not total 100% due to rounding. 1 respondent selected "Other" (No, my organization does not have a specific process/guidance in place for approval of PIE materials, but we would like to develop one).

N=57.

Q18d. Is there a specific process/guidance (eg, standard operating procedure, formal committee) in place within your organization to approve materials intended for PIE?



Formulary Decisions


AmerisourceBerger

CONFIDENTIAL

10

Illustrative PIE Operating Procedure





Potential interaction points between content creators and reviewers

- Potential interaction point between teams and Medical, Legal,
- Regulatory and Promotional/Advertising Regulatory Committee



Formulary Decisions

PROCESS

2




PLANNING



Polling Question for Manufacturers


Have you included PIE in your launch strategy?





Polling Question for Payers

Is there is a gap between the PIE you require and the information you are currently receiving from manufacturers?





Considerations for PIE roadmap



Manufacturers should engage with payers at least 12–18 months in advance of FDA approval to better understand payer needs





Formulary Decisions

EXECUTION OF PIE



Payers consider product pricing, general product information, and study results the most important types of pre-approval information

4% 90% 6% Product pricing 2% Product information 82% 16% Factual presentations of study results 80% 20% 74% 2% 24% Anticipated FDA approval/clearance/licensure timeline 2% 70% Information about the indication(s) sought 28% 64% 34% 2% Patient utilization projections Product-related programs or services 24% 36% 40%

Importance in Receiving Certain Information Pre-approval

Extremely/Very important Somewhat important Not at all/Not very important

Note: Percentages may not total 100% due to rounding.

N=50.

18

Q16a: For each of the following, please rate the level of importance to your organization in receiving this information proactively and prior to approval from a manufacturer.

CONFIDENTIAL




Formulary Decisions

AmerisourceBerger

What manufacturers are delivering...



Types of Information Approved for PIE Discussions



Note: 1 respondent selected "Other" (Distribution strategy/REMS plans [if applicable]).

N=57.

Q20. Which, if any, of the following types of information about investigational products are approved in your organization for PIE discussions with eligible entities?




CONFIDENTIAL



Questions?

How to Ask a Question





What do the next 3-5 years look like?





Thank You









Lisa Cashman, PharmD, Vice President, Specialty Solutions, MedImpact Healthcare Systems

Laura Randa, Vice President Market Access, HEOR and Public Policy, Mycovia Pharmaceuticals Jay Jackson, PharmD, MPH, Senior Vice President, Consulting, Xcenda Jay.Jackson@xcenda.com

Laurie Fazio, Head, FormularyDecisions Market Access Solutions & Growth Strategies Laurie.Fazio@xcenda.com





For inquires on the FormularyDecisions platform or questions related to PIE, please: • Email us at insights@xcenda.com





For a list of upcoming webinars, visit <u>www.amcp.org/calendar</u>

